News and Media

Latest News Release
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

Top feature box IMAGE ONLY - COMPANY NEWS

Company News

Cardinal Health Completes Enturia Acquisition
05/12/2008

ChloraPrep® Products Expand Infection Prevention Business

DUBLIN, Ohio, May 12, 2008 — Cardinal Health, a global provider of products and services that improve the safety and productivity of health care, today announced it has completed the acquisition of assets of privately held Enturia, Inc., the manufacturer of infection prevention products sold under the ChloraPrep® brand name.

ChloraPrep® brand products are used widely in U.S. hospitals and surgery centers as a patient preoperative skin preparation to help prevent blood stream and surgical site infections, two of the most common types of health care associated infections (HAIs) among surgery patients. The products use proprietary disposable applicators to deliver a clinically preferred concentration of chlorhexidine gluconate (CHG) that penetrates the first five cell layers of the skin to help reduce skin-dwelling microorganisms that cause infections. The applicator design eliminates direct hand-to-patient contact, helping prevent cross contamination.

The ChloraPrep® product line expands the company’s offerings that help providers lower infection rates. Cardinal Health’s infection prevention portfolio ranges from MedMined™ electronic infection surveillance services to medical products and surgical apparel. Cardinal Health plans to accelerate sales of ChloraPrep® products to both hospital and alternate-care customers through its U.S. and international sales networks.

About Cardinal Health
Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients.  With a focus on making supply chains more efficient, reducing hospital-acquired infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris® IV pumps, Pyxis® automated dispensing systems, MedMined™ electronic infection surveillance service, VIASYS® respiratory care products and the CareFusion™ patient identification system.  The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide.  Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents.  More information about the company may be found at www.cardinalhealth.com.

More Company News
04/13/2021

Cardinal Health (NYSE: CAH) was awarded a $57.8 million contract, including options that if exercised by the U.S. Department of Health and Human Services (HHS) could reach $91.6 million, for the...

04/07/2021

By Victor Crawford, Chief Executive Officer of the Pharmaceutical segment at Cardinal Health

04/07/2021

Cardinal Health (NYSE: CAH) Specialty Solutions today launched Cardinal Health™ Navista™ Tech Solutions (TS), an advanced suite of technology solutions to help community oncologists improve...

03/30/2021

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will...

View all company news »

* Required Fields